Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for Cognitive Impairment in Multiple Sclerosis
NCT00300716Phase 3Completed
- Sponsor
- Oregon Health & Science University
- Start
- Apr 2004
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cognitive dysfunction comparing Memantine with Placebo (2 arms). Primary endpoint: Change in the Paced Auditory Serial Addition Test and the California Verbal Learning Test II at 15 weeks. Started Apr 2004; status: completed.
02
Drugs
memantine
03
Conditions
cognitive dysfunction
Beyond the preview
Go deeper on NCT00300716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300716.